In the 80-week head-to-head trial, Lilly reports up to 47.4 pounds lost on retatrutide versus 20.9 on Ozempic, plus a bigger drop in A1C.
Recap by typeshit. Full story at Yahoo.
She separates FDA-approved drugs from animal-only and internet-hype compounds, from BPC-157 and Epitalon to retatrutide, and stresses that mechanism isn't proof.
Lilly's experimental weekly shot also lowered blood sugar a bit more than Ozempic in adults with type 2 diabetes, per the shared study report.
Twelve Novo abstracts head to Denver, including a 5,000-patient records study comparing semaglutide and resmetirom, plus four on efruxifermin.
Zeus Hygia reports its berberine extract raised GLP-1 levels in a 14-day, 36-person trial, but warns brands against 'nature's Ozempic' comparisons.
Business Day says medicines endorsed by the WHO still aren't available to public sector patients. The drugs involved aren't named in the share.
Lilly reports adults with type 2 diabetes lost 19.5% to 20.9% of body weight on retatrutide versus 9.4% on Ozempic 2 mg at 80 weeks, with a 2.2% A1C drop.
Loading…